Alvotech (ALVO) - News Archive

Alvotech s Strategic Debt Refinancing: A Major Step Towards Enhanced Financial Stability and Continued Innovation in Biosimilar Medicines In a significant financial milestone, Alvotech (NASDAQ: ALVO), a global biotech c...

Alvotech, a global player in the biotech space, has recently announced positive topline results from a pivotal confirmatory study for its biosimilar candidate, AVT03. This product is designed as a proposed biosimilar to...

Alvotech, a global biotech company specializing in biosimilar medicines, has recently issued new shares to holders of subordinated convertible bonds. This move aims to enhance the company s financial stability and suppo...

Alvotech, a renowned biotech company specializing in the development and production of biosimilar medicines, has recently announced its remarkable second-quarter financial results for 2024. The company s unaudited finan...

Alvotech, a leading global biotech company focused on developing and manufacturing biosimilar medicines, has recently made significant developments that will impact its future growth and financial strength. This article...

In a strategic move to expand their biosimilar portfolio, Alvotech and Advanz Pharma have joined forces to exclusively supply and commercialize Alvotech s upcoming biosimilar to Eylea, a widely used medicine for various...

Strengthening Strategic Alliances: Alvotech and STADA Expand Partnership with Denosumab Biosimilar InitiativeIn a decisive move to enhance their commitment to providing high-quality, cost-effective biosimilars, Alvotech...

Alvotech, a global biotech company specializing in biosimilar medicines, has recently unveiled a strategic refinancing transaction that promises to bring several benefits to the organization. Led by GoldenTree Asset Man...

As a leading global biotech company focused on the development and manufacturing of biosimilar medicines, Alvotech continues to make significant strides in expanding its reach and impact within the healthcare industry....

Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S. REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 In a significant advancement for the treatment of several chronic inflammat...

In a groundbreaking turn of events, INVNT, the renowned global live brand storytelling agency, has been announced as the sponsor and co-producer of the highly anticipated Discovery Stage at SXSW Sydney 2024. Adding furt...

In recent news, Alvotech S.A., a global biotech company, has revealed several significant developments that will have a considerable impact on the company s growth and contribution to global healthcare. With the announc...

Alvotech Announces Webcast of First Quarter 2024 Financial ResultsAlvotech, a global biotech company focused on the development and production of biosimilar medicines, has revealed plans to release its first quarter fin...

In recent news, Alvotech, a renowned global biotech company specializing in biosimilar medicines, has announced its active participation in the highly anticipated BofA Securities Healthcare Conference 2024. The conferen...

/Summary:In a recent disclosure, global biotech company Alvotech, known for its proficiency in developing and manufacturing biosimilar medicines, announced a strategic partnership with Teva Pharmaceuticals. Under this a...

Alvotech, a leading global biotech company focusing on the development and production of biosimilar medicines, has recently released positive topline results from a confirmatory clinical study for AVT05, their proposed...

The contemporary landscape of autism care has taken a surprising shift, as new practice guidelines from Catalight highlight the benefits of decrement in treatment hours and increased parent-mediated care. Concurrently,...

Alvotech, a global biotech company focused on the development and manufacturing of biosimilar medicines, has recently signed a long-term agreement with a strategic partner to improve access to Adalimumab-ryvk in the U.S...

In a significant step for psoriasis treatment, Alvotech and the U.S division of Teva Pharmaceutical Industries Ltd recently received a nod of approval from the U.S. Food and Drug Administration (FDA) for their innovativ...

Alvotech Increases Own Shares with $15.98 Issuance Price to Grow Share CapitalAlvotech, a leading biotech company specializing in biosimilar medicines, has announced a significant increase in its own shares. The company...